PHENYTEK™ (phenytoin sodium) is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.
PHENYTEK™ CAPSULES (extended phenytoin sodium capsules, USP) are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY sections).
Published Studies Related to Phenytek (Phenytoin)
The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. [2011.10]
AIM: The aim of the study was to evaluate the effect of topical phenytoin on healing in diabetic foot ulcers. A randomized, controlled, double-blind, clinical trial was conducted... CONCLUSIONS: There were no differences in diabetic foot ulcer closure rates or in diabetic foot ulcer area over time between the two groups. This study does not support the use of phenytoin in the treatment of diabetic foot ulcers. (c) 2011 The Authors. Diabetic Medicine (c) 2011 Diabetes UK.
Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. [2011.07]
PURPOSE: Statins and antiepileptic drugs (AEDs) are frequently coprescribed to individuals with hypercholesterolemia and new-onset seizures...
Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. [2011.04.12]
OBJECTIVE: Gingival overgrowth is an important adverse effect of phenytoin (PHT) therapy, occurring in about half of the patients. This study aimed to evaluate the effect of oral folic acid supplementation (0.5 mg/day) for the prevention of PHT-induced gingival overgrowth (PIGO) in children with epilepsy aged 6-15 years on PHT monotherapy for 6 months... CONCLUSIONS: Oral folic acid was found to decrease the incidence of PIGO in children on PHT monotherapy, in a statistically significant and clinically relevant manner. Classification of evidence: This study provides Class I evidence that folic acid supplementation, 0.5 mg/day, is associated with prevention of gingival overgrowth in children taking PHT monotherapy.
Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. [2011.02]
By reducing neuronal excitability through selective binding to the alpha(2)delta subunit of voltage-dependent calcium channels, pregabalin effectively treats epilepsy, chronic pain, and anxiety disorders. To evaluate if pregabalin coadministration affects pharmacokinetics of other antiepileptic drugs, population pharmacokinetic analyses using NONMEM software were performed on data from three epilepsy trials involving seven antiepileptic drugs with pregabalin as add-on therapy...
Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? [2010.10]
CONCLUSION: Despite the lack of high-quality clinical trial data, pharmacological knowledge and animal studies suggest that phenobarbital or thiopentone should be second-line agents for controlling toxicological seizures. The role of newer agents such as propofol and levetiracetam in toxicological seizures is currently unclear because of a lack of clinical or animal studies.
Clinical Trials Related to Phenytek (Phenytoin)
Bioequivalence Study Of Phenytoin Suspension Versus EpaminŽ In 34 Healthy Volunteers. [Recruiting]
Mexican healthy volunteers will receive the current form of the drug (under the name of
Epamin) as well as Pfizer's compound (Phenytoin). Bioequivalence will be tested.
Phenytoin as a Neuroprotective Agent Against Corticosteroid-Induced Functional Imaging Changes [Recruiting]
The purpose of this research is to determine if patients who receive phenytoin (also
commonly known as Dilantin) before taking corticosteroids will show less memory impairment
and hypomanic symptoms (feelings of agitation, overexcitement or hyperactivity) than those
receiving placebo (an inactive substance). This research also seeks to determine if
patients taking phenytoin before corticosteroids show more activity in the area of the brain
involved with memory than those receiving placebo.
This research is being done because increased levels of cortisol (the body's natural
corticosteroid) in the body are frequently associated with forgetfulness, and interventions
that may prevent or reverse this effect are of great importance.
Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. [Recruiting]
To evaluate the efficacy of the prophylaxis with phenytoin in the prevention of seizures in
patients with pneumococcal meningitis. Hypothesis: Administration of prophylactic phenytoin
will reduce the incidence of seizures in patients with pneumococcal meningitis older than 50
Neuroprotection With Phenytoin in Optic Neuritis [Not yet recruiting]
Optic neuritis is caused by inflammation of the optic nerve and causes loss of vision in the
affected eye. It is often associated with multiple sclerosis. Loss of vision after an attack
of optic neuritis is caused by damage to the nerve fibres in the optic nerve. There are a
number of factors that contribute to nerve fibre damage including increased levels of sodium
within them, so blocking sodium entry could help to protect them against damage.
The purpose of this study is determine whether phenytoin (which blocks sodium entry into
cells) can protect against loss of nerve fibres and prevent loss of vision after optic
Phenytoin and Driving Safety [Recruiting]
Automobile driving is a crucial aspect of everyday life, yet vehicular crashes represent a
serious public health problem. Patients with epilepsy are at elevated risk for automobile
crashes, causing great personal suffering and financial costs to society. Most collisions
involving epileptic drivers are not seizure related but may instead result from cognitive
effects upon driving performance of epilepsy and antiepileptic drugs (AEDs). Several million
American drivers take AEDs for treatment of medical conditions besides epilepsy and may also
be at risk for cognitive impairments that can reduce driving performance. Empirical evidence
of the effects of AEDs on driving performance would enable development of driving guidelines
that could lower the risk of injurious motor vehicle collisions; however, this evidence is
currently lacking. The broad goal of our project is to determine the specific effects of the
most commonly utilized AED, phenytoin, by assessing driving performance and cognitive
abilities in neurologically normal volunteers taking phenytoin in a randomized,
double-blind, placebo-controlled, crossover study. Our proposed experiments will assess: (1)
cognitive functions using standardized neuropsychological tests (of attention, perception,
memory, and executive functions), (2) driving performance during phenytoin and placebo
administration, and (3) the effects of phenytoin-related cognitive performance upon driving
performance. To measure driving performance, we will use a state-of-the-art fixed-base
interactive driving simulator that allows us to observe driver errors in an environment that
is challenging yet safe for the driver and tester, under conditions of optimal stimulus and
response control. The results of this study of 30 drivers treated with phenytoin and placebo
will increase the understanding of the role of AED-related cognitive impairment on driving
safety errors. A better understanding of the impact of AEDs upon driving performance is
necessary to rationally develop interventions that could help prevent crashes by drivers
treated with AEDs.
Reports of Suspected Phenytek (Phenytoin) Side Effects
Loss of Consciousness (5),
Balance Disorder (4),
Drug Level Fluctuating (2),
Coordination Abnormal (2),
Back Pain (2),
Pain in Extremity (2), more >>
Page last updated: 2011-12-09